State Street Corp Has $30.24 Million Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

State Street Corp cut its holdings in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 11.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,476,292 shares of the biopharmaceutical company's stock after selling 444,371 shares during the period. State Street Corp owned approximately 2.23% of Ocular Therapeutix worth $30,244,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in OCUL. Atlas Capital Advisors LLC acquired a new position in Ocular Therapeutix during the 2nd quarter valued at about $34,000. Amalgamated Bank boosted its holdings in shares of Ocular Therapeutix by 37.9% in the second quarter. Amalgamated Bank now owns 5,384 shares of the biopharmaceutical company's stock valued at $37,000 after acquiring an additional 1,481 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Ocular Therapeutix by 22.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,639 shares of the biopharmaceutical company's stock valued at $49,000 after acquiring an additional 1,015 shares during the period. Algert Global LLC bought a new stake in Ocular Therapeutix during the second quarter worth approximately $69,000. Finally, Capital Performance Advisors LLP acquired a new stake in Ocular Therapeutix in the third quarter worth approximately $70,000. 59.21% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Ocular Therapeutix

In other news, insider Jeffrey S. Heier sold 2,948 shares of the business's stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $9.01, for a total transaction of $26,561.48. Following the sale, the insider now owns 269,059 shares in the company, valued at $2,424,221.59. The trade was a 1.08 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 3.50% of the stock is currently owned by corporate insiders.

Ocular Therapeutix Price Performance

Shares of NASDAQ OCUL traded up $0.05 during mid-day trading on Friday, reaching $8.50. The company had a trading volume of 1,431,144 shares, compared to its average volume of 1,767,917. The company has a 50-day moving average price of $9.98 and a two-hundred day moving average price of $8.62. The stock has a market cap of $1.34 billion, a PE ratio of -6.44 and a beta of 1.19. The company has a current ratio of 13.01, a quick ratio of 12.94 and a debt-to-equity ratio of 0.19. Ocular Therapeutix, Inc. has a 1-year low of $3.76 and a 1-year high of $11.77.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. HC Wainwright reiterated a "buy" rating and set a $15.00 price target on shares of Ocular Therapeutix in a research report on Tuesday, December 3rd. Scotiabank initiated coverage on Ocular Therapeutix in a report on Wednesday, October 16th. They set a "sector outperform" rating and a $22.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company's stock. According to MarketBeat, Ocular Therapeutix presently has a consensus rating of "Moderate Buy" and an average target price of $16.71.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.